Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
Titel:
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
Auteur:
Heinrich, Kathrin Modest, Dominik P. Ricard, Ingrid Fischer von Weikersthal, Ludwig Decker, Thomas Kaiser, Florian Graeven, Ullrich Uhlig, Jens Schenk, Michael Freiberg-Richter, Jens Peuser, Bettina Denzlinger, Claudio Giessen-Jung, Clemens Stahler, Arndt Michl, Marlies Held, Swantje Jung, Andreas Kirchner, Thomas Stintzing, Sebastian Heinemann, Volker